China Neurogenomics Market (2024-2031)
The China Neurogenomics Market was valued at $136.4 million in 2023. This market is expected to reach $562.1 million by 2031 from an estimated $162.1 million in 2024, at a CAGR of 19.4% during the forecast period 2024–2031. China Neurogenomics Market Size & Forecast The growth of the China neurogenomics
- Published
- Oct 2024
- Pages
- 140
- Format
- PDF + Excel
- Report ID
- MRHC - 1041320
- Base year
- 2023
- 2023 · BASELINE
- $136.4M
- 2031
- $562.1M
- CAGR 2024–2031
- 19.4%
2023 baseline · 2024–2031 forecast at 19.4% CAGR · hover a bar for the value
Key highlights
Based on Offering: The Next-generation Sequencing (NGS) Segment to Dominate the China Neurogenomics Market in 2024
Based on Application: The Research Applications Segment to Dominate the China Neurogenomics Market in 2024
Based on End User: The Pharmaceutical & Biotechnology Companies Segment to Dominate the China Neurogenomics Market in 2024
Report summary
| Particulars | Details |
|---|---|
| Number of Pages | 140 |
| Format | |
| Forecast Period | 2024–2031 |
| Base Year | 2023 |
| CAGR (Value) | 19.4% |
| Market Size (Value) | $562.1 Million by 2031 |
| Segments Covered | By Offering · Next-generation Sequencing · Systems · Kits & Reagents · DNA Extraction and Amplification Kits & Reagents · Library Preparation and Target Enrichment Kits & Reagents · Quality Control Kits & Reagents · Other NGS Kits & Reagents · Polymerase Chain Reaction (PCR) · Systems · Kits & Reagents · Microarray · Readers & Scanners · Kits & Reagents · DNA and RNA Microarray Kits & Reagents · Protein Microarray Kits & Reagents · Tissue Microarray Kits & Reagents · Software & Services · By Application · Research Applications · Target identification · Functional Studies · Variant Discovery · Transcription Factor Binding Analysis · Clinical Applications · By End User · Pharmaceutical & Biotechnology Companies · Academic & Research Institutes · Hospitals & Diagnostic Laboratories |
| Key Companies Profiled | Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Revvity, Inc. (U.S.), Pacific Biosciences of California Inc. (U.S.), Danaher Corporation (U.S.), Oxford Nanopore Technologies Plc. (U.K.), and MGI Tech Co., Ltd. (China) |
Report overview
Segments covered: offering, application, end user.
The growth of the China neurogenomics market is driven by the declining costs of sequencing, the increasing prevalence of neurological disorders, the growing utilization of advanced sequencing technologies in disease diagnostics & precision medicine, increasing pharmaceutical R&D expenditures, improvements in regulatory & reimbursement scenarios for gene sequencing, rising healthcare expenditures, increasing funding for research activities, the growing need for the early detection & prevention of neurological diseases, technological advancements in neurogenomics products, and government initiatives promoting the use of sequencing in clinical & research applications. However, the high prices of neurogenomics products, the low chances of identifying positive actionable mutations for precision medicine, and ethical & legal issues related to sequencing-based diagnosis restrain the growth of this market.
Furthermore, the increasing adoption of targeted therapies, emerging economies, and rising awareness regarding neurological disorders are expected to create market growth opportunities. However, the dynamic regulatory landscape, the limited expertise & sequencing capabilities of small & medium-sized laboratories, the shortage of sequencing professionals in the country, and the high capital investments required for sequencing setups are major challenges in the China neurogenomics market.
Report infographic
Market dynamics
3 factors across 2 forcesGrowing Utilization of Advanced Sequencing Technologies in Disease Diagnostics & Precision Medicine
Precision medicine is an emerging approach to patient care. Physicians choose a treatment method based on the patient’s genetic makeup, also considering genetic changes resulting from a disease and lifestyle habits. It is an emerging disease treatment & prevention approach that considers variability in genes, environments, and lifestyles among individuals. Precision medicine can reduce the need for guesswork (trial and error in medication depending on how the medication affects the patient’s symptoms), help physicians overcome challenges related to variable diagnostic ability, and aid the development of treatment strategies based on generalized demographics. Moreover, precision medicine provides a more holistic view of an individual’s health. In clinical neurogenomics workflows, precision medicine facilitates more predictive and preventive care through targeted therapies. Major advantages of precision medicine for neurological conditions include reductions in trial & error prescriptions, avoidance of adverse drug reactions, increased patient adherence to treatment due to fewer side effects, a decrease in the prescription of unnecessary drugs to non-responder patients, and optimization of drug development costs.
Increasing Prevalence of Neurological Disorders
China accounts for approximately 17% of the global disease burden related to neurological, mental, and substance use disorders. The country is rapidly undergoing a societal change, facing challenges in reducing the disease burden of psychiatric disorders. The increasing cases of neurological disorders have increased the burden on the country’s healthcare system, further boosting the demand for more advanced diagnostic solutions. For instance, China faces the greatest burden of stroke globally. According to results from the Global Burden of Disease Study 2019, there were 3.94 million new stroke cases, 28.76 million prevalent stroke cases, and 2.19 million deaths due to stroke in China in 2019 (Source: Data Management and Sharing System of the China National Clinical Research Center for Neurological Diseases).
Furthermore, cases of Alzheimer’s disease are adding to the growing burden of neurological diseases in the country. According to a recent national cross-sectional study, China has 15.07 million individuals aged 60 years and over with dementia, which includes 9.83 million individuals with Alzheimer’s disease, 3.92 million individuals with vascular dementia, and nearly 1.32 million individuals with other forms of dementia. Thus, the increasing burden of neurological disorders is expected to boost the demand for advanced neurological solutions in the country.
Table of contents
10 chapters · 74 sections · 140 pages · click to expandSegmental analysis
| Segment | Largest share (2024) | Fastest growth (2024–2031) |
|---|---|---|
| By Offering | Next-generation Sequencing (NGS) | NGS |
| By Application | Research Applications | — |
| By End User | Pharmaceutical & Biotechnology Companies | Academic & research institutes |
By Offering
- The Next-generation Sequencing (NGS) segment is expected to account for the largest share of 64.1% of the China neurogenomics market.
- The segment’s substantial market share is primarily attributed to the recurring demand for consumables, increasing sequencing-based clinical & research applications of neurogenomics, and the growing preference for sequencing-based diagnostics.
- Moreover, the NGS segment is also expected to record the highest CAGR during the forecast period due to the increasing demand for NGS consumables, the higher accuracy of NGS compared to other sequencing technologies, and the increasing number of genomics projects based on sequencing.
By Application
- The research applications segment is further segmented into functional studies, target identification, variant discovery, and transcription factor binding analysis.
- The research applications segment is expected to account for the larger share of 61.4% of the China neurogenomics market.
- The segment’s large share is attributed to the extensive use of NGS, PCR, and microarray solutions in research to identify specific genes and their sequences to gain a better understanding of the mechanisms underlying complex neurological diseases such as Parkinson's disease, Alzheimer's disease, Amyotrophic Lateral Sclerosis (ALS), and psychiatric disorders.
- Moreover, the research applications segment is expected to record the higher CAGR during the forecast period due to the rising demand for advanced research solutions among laboratories to develop treatments for neurological conditions, the increasing demand for personalized medicine, and research studies to identify specific gene mutations in complex neurological diseases such as Alzheimer’s disease and Parkinson’s disease.
By End User
- The pharmaceutical & biotechnology companies segment is expected to account for the largest share of 44.5% of the China neurogenomics market.
- The segment’s large share is primarily attributed to pharmaceutical & biotechnology companies’ high adoption of advanced technologies for research, the high availability of capital for research, increasing research for drug discovery, and the widening applications of NGS.
- However, the academic & research institutes segment is expected to record the highest CAGR during the forecast period due to the rising number of research centers in China, increasing private & government funding for neurogenomics research, and the increasing utilization of advanced solutions by academic & research institutes.
Competitive landscape
- January 2024
Illumina, Inc. (U.S.) partnered with Haplox, officially known as Shenzhen Hipros Biotechnology Co., Ltd (China), to develop and launch NextSeq 2000 Dx CN-HAP, the first benchtop genetic sequencing technology of its kind.
- March 2023
Illumina, Inc. (U.S.) launched the Connected Insights cloud-based software designed for tertiary analysis of clinical next-generation sequencing data. This platform supports applications in somatic oncology and whole-genome sequencing for rare diseases and streamlines clinical reporting by integrating third-party knowledge bases, thereby reducing turnaround times.
- October 2023
Thermo Fisher Scientific, Inc. (U.S.) acquired Olink Proteomics AB, a Sweden-based company specializing in advanced proteomics discovery and development. Olink operates across the Americas, Europe, and Asia-Pacific, expanding Thermo Fisher's capabilities in the field of proteomics.
- March 2022
Thermo Fisher Scientific, Inc. (U.S.) launched the Ion Torrent Genexus Dx Integrated Sequencer, an automated Next-generation Sequencing (NGS) platform capable of delivering results within a single day.
- Illumina, Inc. (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
- F. Hoffmann-La Roche Ltd · Switzerland
- QIAGEN N.V. · Netherlands
- Agilent Technologies, Inc. (U.S.)
- Revvity, Inc. (U.S.)
- Pacific Biosciences of California Inc. (U.S.)
- Danaher Corporation (U.S.)
- Oxford Nanopore Technologies Plc. (U.K.)
- MGI Tech Co., Ltd. · China
Frequently asked questions
The China neurogenomics market study focuses on market assessment and opportunity analysis based on the sales of neurogenomics products across various market segments in China. The report also includes a competitive analysis based on the leading market players’ product portfolios and key growth strategies adopted in the last 3–4 years.
Cite this report
Meticulous Research. (2024). China Neurogenomics Market - Opportunity Analysis and Industry Forecast (2024-2031) (Report No. MRHC - 1041320). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/china-neurogenomics-market-6003